tbuckley/cabot-search huggingface dataset:
Predictors of mortality in cancer patients with sepsis.
Authors: Ludhmila A Hajjar, Clarice H Park, Eduardo A Osawa, Danielle Nagaoka, Julia Tizue Fukushima, Rosana Nakamura, Gisele Queiroz, Juliano Almeida, Brunna Pileggi, Filomena Galas, Ana Paula Souza, Maria Del Pilar Estevez-Diz
Journal: Journal of Clinical Oncology (2014)

e20714 Background: Cancer patients with sepsis have elevated mortality rates and there are few prediction models of mortality available in this population. Several scores validated in the general ICU did not show good accuracy in cancer patients. The aim of this study was to identify clinical and laboratory predictors of sepsis mortality in a oncologic population. Methods: We performed a retrospective study of 246 patients admitted with severe sepsis or septic shock in the Intensive Care Unit (ICU) of Institute of Cancer of Sao Paulo, Brazil from February 2011 to December 2012. Results: In this population, the median age was 61 years, 129 patients (52.4%) were male, 104 patients (42.2%) had metastasis, 53 patients (21.5%) presented with febrile neutropenia and the mortality rate was 50%. Upon ICU admission, 147 patients (59.7%) had cardiovascular failure, 100 (40.6%) had respiratory failure, 105 (42.6%) had renal failure, 57 (23.1%) had liver failure, 80 (32.5%) had decreased level of consciousness and 100 (40.6%) had hematologic dysfunction. During ICU stay, 23 patients (9.3%) needed hemodialysis, 77 (31.3%) needed mechanical ventilation, 168 (68.3%) used vasoactive agents and 35 (14.2%) received limitation of medical treatment. Multivariate logistic analysis of admission variables showed that respiratory failure (OR 3.528 [95% CI:1.856-6.706], p<0.001), creatinine level (OR 1.222 [95%CI:1.008-1.482], p<0.041), lactate level (OR 1.024 [95% CI:1.009-1.040], p 0.002) and low serum albumin level (OR 4.081 [95%CI:2.358-7.042], p<0.001) were independent predictors of mortality. A predictive model of mortality was generated by combining these variables and showed AUC-ROC=0.79 CI95% (0.74-0.86). Conclusions: Given the heterogeneous presentation and the presence of prognostic issues involving cancer patients such as disease progression and functional status, development of a prediction model of mortality could guide ICU resource allocation in cancer patients with sepsis.
Multiple primary cancer in adults (MPCA)
Authors: S. L. Ares, S. Polo, L. Ezcurdia, F. Tognelli, S. Mussini, N. Gercovich, E. Rivarola, E. Morgenfeld, E. Gil Deza, F. G. Gercovich
Journal: Journal of Clinical Oncology (2006)

16027 Background: As a result of the improvement in oncological treatments, MPCA could arise as a more frequent problem in Public Health. The purpose of this retrospective review was to estimate both the incidence and medical features of MPCA pts treated at the Instituto Oncológico Henry Moore (IOHM). Methods: We analyzed 17,100 medical charts from our database since 1987 and identified 378 MPC (2,21%). Then we retrieved data over the last eight years (1997–2005). Those pts with at least two second primary tumors were included in this analysis. They were categorized as synchronous (second tumor diagnosis within the first six months from the first one) and metachronous (all the remaining). Pts with skin cancer different from melanoma were excluded. Results: One hundred and seventy eight (M:73; F:105) out of 8,500 cancer pts (2.09%) had at least two primary cancers. Median age was 59, 64 and 68 yo at the moment of the first, second and third diagnosis, respectively. In 138 (78%) pts, the diagnosis of the second cancer was suspected by clinical findings, while in 40 (22%) pts, it was discovered because of medical screening in an otherwise asymptomatic pt. (See Table below) The most frequent site combination was breast-breast (n = 21). A total of 57 pts (32%) had a family history of oncologic diseases. With a median follow-up of 31 mo (range: 0,57–311) after the second cancer diagnosis, 127 pts are still alive (71,35%) and 51 (28,65%) are dead. Conclusions: In the last eight years, 178 (2.09%) pts had developed MPC, being breast, prostate, colon and lung the most frequent (first and later) localizations, and breast-breast the most frequent site combination. The so-called “screening effect” seems to have a low impact on the studied population. [Table: see text] No significant financial relationships to disclose.
NCCN Guidelines Insights: Bladder Cancer, Version 2.2016
Authors: Peter E Clark, Philippe E Spiess, Neeraj Agarwal, Rick Bangs, Stephen A Boorjian, Mark K Buyyounouski, Jason A Efstathiou, Thomas W Flaig, Terence Friedlander, Richard E Greenberg, Khurshid A Guru, Noah Hahn, Harry W Herr, Christopher Hoimes, Brant A Inman, A Karim Kader, Adam S Kibel, Timothy M Kuzel, Subodh M Lele, Joshua J Meeks, Jeff Michalski, Jeffrey S Montgomery, Lance C Pagliaro, Sumanta K Pal, Anthony Patterson, Daniel Petrylak, Elizabeth R Plimack, Kamal S Pohar, Michael P Porter, Wade J Sexton, Arlene O Siefker-Radtke, Guru Sonpavde, Jonathan Tward, Geoffrey Wile, Mary A Dwyer, Courtney Smith
Journal: Journal of the National Comprehensive Cancer Network (2016)

These NCCN Guidelines Insights discuss the major recent updates to the NCCN Guidelines for Bladder Cancer based on the review of the evidence in conjunction with the expert opinion of the panel. Recent updates include (1) refining the recommendation of intravesical bacillus Calmette-Guérin, (2) strengthening the recommendations for perioperative systemic chemotherapy, and (3) incorporating immunotherapy into second-line therapy for locally advanced or metastatic disease. These NCCN Guidelines Insights further discuss factors that affect integration of these recommendations into clinical practice.
Neurotoxicity (NT) in colon cancer (CC) survivors from NSABP Protocol C-07 comparing 5-FU + leucovorin (FULV) with the same regimen + oxaliplatin (FLOX): Preliminary results from NSABP Protocol LTS-01
Authors: G. Yothers, S. R. Land, P. A. Ganz, L. Fehrenbacher, J. K. Giguere, D. L. Wickerham, C. Y. Ko
Journal: Journal of Clinical Oncology (2008)

9575 Background: NT is an important acute toxicity associated with oxaliplatin therapy, yet little is known about NT in long term CC survivors treated with oxaliplatin as part of adjuvant therapy. NSABP LTS-01 is a comprehensive study examining patient reported outcomes (PROs) in long term survivors (LTS) of colon and rectal cancer previously treated on NSABP adjuvant trials. We report preliminary NT PRO results from LTS-01 for patients (pts) accrued to C-07 from 2000–2002. Methods: Eligible C-07 pts were recruited and consented by NSABP investigators providing regular follow-up. After consent, telephone interviews were used to collect PROs including NT by the validated FACT/GOG Oxaliplatin-Specific NT questionnaire (NTX-12). A subset of pts completed the NTX-12 as part of the original C-07 trial. Statistical comparisons of NT across treatments (TX) used the Wilcoxon test. Results: LTS-01 opened in Oct 06 and, as of Dec 07, NT PRO data are available from 280 pts (51% on FLOX). Characteristics were similar across TX with 50% of pts over age 65, 92% white, 96% non-Hispanic, 8% with CC recurrence, and 12% with new primary cancer. Median time from C-07 randomization to LTS-01 interview was 6 years. FLOX pts had more NT than FULV pts (p = 0.014), but the mean difference in NTX-12 score was 1.8, less than the 4 points considered clinically important. Individual item scores with significantly more NT on FLOX included: numbness/tingling in hands (31 v 44% with any severity, p = .017), numbness/tingling in feet (22 v 46%, p < 0.0001), and pain in hands/feet when exposed to cold (26 v 43%, p = 0.010). In the subset of 79 pts with baseline (BL) NTX-12 data (54% FLOX), the change from BL score was similar for both TX. In a subset of 34 FLOX pts with 18-month data, NT was similar at 18 months and the LTS assessment at 5–7 years. Conclusions: While small differences in oxaliplatin-induced NT persist to 6 years, they fail to reach clinical significance. Numbness, tingling, and cold-induced pain of the hands and feet remain a problem for some long term CC survivors treated with oxaliplatin. Supported by grants from the NCI and the American Cancer Society. No significant financial relationships to disclose.
Outcome Of Bone Marrow Transplantation In Lebanese Children With β-Thalassemia Major
Authors: Adlette Inati, Javid Gaziev, Hussein A Abbas, Serge Korjian, Yazan Daaboul, Mario Kahale, Katia Paciaroni, Gioia de Angelis, Ali T Taher, Therese Abi Nasr, Suzan Koussa, Guido Lucarelli
Journal: Blood (2013)
Athletic groin pain (part 2): a prospective cohort study on the biomechanical evaluation of change of direction identifies three clusters of movement patterns
Authors: A Franklyn-Miller, C Richter, E King, S Gore, K Moran, S Strike, E C Falvey
Journal: British Journal of Sports Medicine (2016)

Background Athletic groin pain (AGP) is prevalent in sports involving repeated accelerations, decelerations, kicking and change-of-direction movements. Clinical and radiological examinations lack the ability to assess pathomechanics of AGP, but three-dimensional biomechanical movement analysis may be an important innovation. Aim The primary aim was to describe and analyse movements used by patients with AGP during a maximum effort change-of-direction task. The secondary aim was to determine if specific anatomical diagnoses were related to a distinct movement strategy. Methods 322 athletes with a current symptom of chronic AGP participated. Structured and standardised clinical assessments and radiological examinations were performed on all participants. Additionally, each participant performed multiple repetitions of a planned maximum effort change-of-direction task during which whole body kinematics were recorded. Kinematic and kinetic data were examined using continuous waveform analysis techniques in combination with a subgroup design that used gap statistic and hierarchical clustering. Results Three subgroups (clusters) were identified. Kinematic and kinetic measures of the clusters differed strongly in patterns observed in thorax, pelvis, hip, knee and ankle. Cluster 1 (40%) was characterised by increased ankle eversion, external rotation and knee internal rotation and greater knee work. Cluster 2 (15%) was characterised by increased hip flexion, pelvis contralateral drop, thorax tilt and increased hip work. Cluster 3 (45%) was characterised by high ankle dorsiflexion, thorax contralateral drop, ankle work and prolonged ground contact time. No correlation was observed between movement clusters and clinically palpated location of the participant's pain. Conclusions We identified three distinct movement strategies among athletes with long-standing groin pain during a maximum effort change-of-direction task These movement strategies were not related to clinical assessment findings but highlighted targets for rehabilitation in response to possible propagative mechanisms. Trial registration number NCT02437942, pre results.
Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy
Authors: J. R. Skillings, D. H. Johnson, K. Miller, F. Kabbinavar, E. Bergsland, E. Holmgren, S. N. Holden, H. Hurwitz, F. Scappaticci
Journal: Journal of Clinical Oncology (2005)

3019 Background: BV (Avastin™) is a monoclonal antibody to VEGF with demonstrated survival benefit when combined with CT in metastatic colorectal cancer (mCRC). Individual safety data from several RCT's suggested that adding BV to CT may increase the risk of ATEs. We conducted a pooled analysis to evaluate this potential safety signal. Methods: Data from 1745 pts with metastatic carcinomas (breast, colorectal, and non-small-cell lung) pooled from 5 RCTs of BV with CT were analyzed to assess ATE risk and identify predisposing factors in the context of overall clinical effect. Clinical parameters, including age, gender, development of proteinuria on study, and history of hypertension, diabetes, atherosclerosis, venous TE (VTE), and use of aspirin or a statin, were assessed for relationship to ATE occurrence by univariate analysis and a Cox proportional hazards regression model. Results: Within this pooled population, the addition of BV to CT increased the risk of ATE compared to CT alone (3.8% vs 1.7%, p < 0.01 by Chi-square test). In addition to BV treatment, history of atherosclerosis and age ≥65 were identified as independent risk factors by multivariate analysis (hazard ratios of 1.9, 2.9, and 2.2 respectively). Conclusion: The addition of BV to CT is associated with an increased risk of ATE in pts with metastatic carcinoma, especially those ≥65 years old with a prior history of atherosclerosis. The risk/benefit of BV in mCRC by ATE-risk group will be presented. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genentech AstraZeneca, Genentech, GlaxoSmithKline, Pfizer Genentech AstraZeneca, Genentech, Novartis Bristol-Myers Squibb, Genentech
Predictors of sudden cardiac death change with time after myocardial infarction: Results from the VALIANT Trial
Authors: Jonathan P Piccini, Karen S Pieper, Scott D Solomon, Sana Al-Khatib, Frans Van de Werf, Marc A Pfeffer, John J. McMurray, Robert M Califf, Eric J Velazquez
Journal: Journal of the American College of Cardiology (2008)
An alternative titration schedule of axitinib in metastatic renal cell carcinoma.
Authors: Vyshak Alva Venur, Laura S. Wood, Paul Elson, Allison Martin, Jennifer Beach, Jorge A. Garcia, Brian I. Rini
Journal: Journal of Clinical Oncology (2015)

444 Background: Titration of axitinib for metastatic renal cell carcinoma (mRCC) is currently based on tolerance with escalation from 10 mg/day to 14 mg/day and then to 20 mg/day. However, not all patients who can be titrated upward require a higher dose for response, nor do all patients tolerate the increased dose levels. An alternative titrating strategy was employed based on radiographic response, tolerance, and using intermediate dosing levels. Methods: In this retrospective analysis of mRCC, axitinib was initiated at 10 mg/day (5 mg BID). Response was assessed with CT scans at 6 weeks after each dosing change. Patients with response by MASS criteria and acceptable toxicity (&lt;grade 2) were continued on the same dose. If the patient had no response and &lt;grade 2 toxicity, axitinib was increased by 2 mg/day at each reassessment (e.g., initially to 6 mg BID), to a maximum of 20 mg/day. If the patient had &gt;grade 2 toxicity the dose was reduced by 1 mg/day. Results: Twenty-eight patients were started on axitinib as per the above titration scheme between May 2013 and June 2014. Twenty four patients had clear cell, 3 had papillary and 1 had chromophobe mRCC, and all patients had received at least one prior systemic therapy. The final dose of axitinib ranged from 2 mg/day through 20 mg/day. Eleven patients did not change from the starting dose. Ten patients (36%) underwent dose escalation whereas 7 patients required dose reduction. Overall, for the 17 patients who had their dosage adjusted, the median time to final (current) dose was 9.9 weeks (range, 6.0-23.7), and the median time within a dose was 6.6 weeks (range, 1.1-10.0). Five of 10 patients who required dose escalation ended up on doses other than 14 mg/day or 20 mg/day (three at 12 mg/day and two at 16 mg/day). Among the dose-escalated patients, two patients had grade 1 diarrhea, one each had grade 3 diarrhea, grade 2 diarrhea, grade 1 nausea, grade 2 fatigue, grade 1 hypertension and grade 1 hand foot syndrome. The objective response rate was 17% with a median PFS of 7.4 months. Conclusions: Axitinib dose titration guided by radiographic response and toxicity is a feasible strategy with acceptable overall disease control and good tolerance. A prospective study is warranted.
GSK626616: A DYRK3 Inhibitor as a Potential New Therapy for the Treatment of Anemia.
Authors: Connie L. Erickson-Miller, Caretha Creasy, Antony Chadderton, Christopher B. Hopson, Elizabeth I. Valoret, Michele Gorczyca, Louis Elefante, Don M. Wojchowski, Matthew Chomo, Duke M. Fitch, Kevin J. Duffy
Journal: Blood (2007)
Febuxostat a new weapon in armamentarium of tumor lysis syndrome management: results of Florence pivotal study
Authors: M. Federico, M. Spina, Z. Nagy, J.M. Ribera, I. Aurer, K. Jordan, G. Borsaru, A.S. Pristupa, A. Bosi, S. Grosicki, N.L. Glushko, D. Ristic, J. Mayer, C. Rossi, A. Scordari, S. Baldini, S. Scartoni, C.A. Maggi, A. Capriati, C. Simonelli
Journal: Annals of Oncology (2015)
Multicenter open label study of subcutaneous (SC) omacetaxine (OMA) in imatinib (IM)-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation
Authors: A. Benichou, H. J. Khoury, S. Corm, F. E. Nicolini, A. R. Craig, E. Humphriss, J. E. Cortes
Journal: Journal of Clinical Oncology (2008)

7021 Background: Omacetaxine mepesuccinate (semi-synthetic homoharringtonine, HHT) is clinically active against Ph+ CML, with a mechanism of action independent of tyrosine kinase (TK) inhibition. Currently available TK inhibitors have not demonstrated activity in CML patients with the T315I mutation. We are evaluating the safety/efficacy of SC OMA in Pts with IM-resistant T315I+ Ph+ CML. Methods: Eligible Pts- adult T315I+ CML following imatinib failure or intolerance. Induction schedule: 1.25 mg/m2 SC twice daily (BID) for 14 days every 28 days until complete hematologic response (CHR) or hematologic improvement. Maintenance schedule: 1.25 mg/m2 BID for 7 days every 28 days, for up to 24 mos. Results: To date, 29 Pts have been enrolled, 17 in chronic phase (CP), 6 in accelerated phase (AP) and 6 in myeloid blast phase (BP). Median age: 58 yrs (19–83), median disease duration: 58 mo. (9–287). Overall hematologic response rate: CP 64%, AP 100%, and BP 34%, with 45% CHR in CP patients. Overall cytogenetic response rate (CyR): CP 27% and AP 25%, with 2 complete CyR in CP and 1 minor CyR in AP. Median time to response 2 mo. (1–5), median duration of response 4 mo. (1–13+). Incidence of grade 3/4 events: thrombocytopenia 52%, anemia 43%, neutropenia 43%, febrile neutropenia 22% and diarrhea 17%. Grade 1–2 local injection site pain or erythema in 23% and 13% of cases, respectively. T315I transcript levels are no longer detectable in 50% (7/14) of Pts. Conclusions: OMA therapy in T315I+ IM-resistant CML Pts has been well tolerated and resulted in durable CHRs and cytogenetic responses. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration ChemGenex, Stragen ChemGenex ChemGenex ChemGenex
Evaluation of serum/plasma VEGF/e-selectin and 18F-FDG PET uptake after panitumumab infusion in locally advanced rectal cancer (LARC) patients treated with chemoradiation (CTRT) (StarPan/STAR-02 phase II study).
Authors: S. Pini, F. Di Fabio, P. Di Tullio, E. Bucca, T. Latiano, E. Perrone, M. Gion, E. Maiello, A. Martoni, C. Pinto
Journal: Journal of Clinical Oncology (2010)

3654 Background: The aim of this study was to characterize the changes in circulating VEGF/E-Selectin and 18F-FDG PET uptake produced by panitumumab-based CTRT in LARC pts. Methods: The pts entering the study had rectal adenocarcinoma, cT3N+ or cT4N-/+ stage, with location < 12 cm from the anal margin. Panitumumab was administered at a dose of 6 mg/kg IV, 2 weeks before the start of CTRT, and then in combination with CTRT, 3 times every 2 weeks. CT consisted of 5FU 225 mg/m2/day CI IV days 1-38 and OXA 60 mg/m2 IV weekly six times. RT was delivered at a dose of 50.4 Gy. Rectal surgery was performed 7-8 weeks after the end of CTRT. Serum/plasma VEGF and sE-Selectin levels were determined on day -14 (baseline) and on days 1 (after panitumumab), 8 and 22 (during treatment), and 36 (pre-surgery). Biomarkers levels were assessed using commercial quantitative sandwich enzyme immunoassays (Quantikine Human VEGF Immunoassay, R&D Systems; Human sE-selectin ELISA, Bender MedSystems). 18F-FDG-PET scan evaluation was performed at baseline, after the first panitumumab administration (on days -1, -2). Results: Sixty-two pts were enrolled from February 2007 to October 2009. Pt characteristics were: males 34 (54.8%), females 28 (45.2%); median age 59 (38-73); clinical stage: T3 46 (74.6%), T4 16 (25.4%), N- 8 (13.6%), N+ 54 (86.4%). Twenty-four pts, enrolled in two Centers, were available for VEGF/E-Selectin evaluations and 25 pts for PET study. The mean basal values of biomarkers (at day -14) were: serum VEGF 439.1 pg/mL, plasma VEGF 177.2 pg/mL, serum sE-Selectin 37.5 ng/mL. On day 1 the VEGF and sE-Selectin mean value presented higher levels as compared with baseline: serum VEGF +41.7% (p = 0.047), plasma VEGF +129.6% (p = 0.708), sE-Selectin +50.6% (p < 0.001). The median SUV of PET scan decreased from 14 (range 6.1-26.9) at baseline to 10.5 (range 1.9-25.2) after panitumumab administration (p = 0.005). Conclusions: In these preliminary data, panitumumab monotherapy increased plasma/serum VEGF and sE-Selectin and decreased the 18F-FDG uptake. The results of the tumor pathological response will be available for the 2010 ASCO Meeting. No significant financial relationships to disclose.
Internet Gaming Disorder: Investigating the Clinical Relevance of a New Phenomenon
Authors: Andrew K. Przybylski, Netta Weinstein, Kou Murayama
Journal: American Journal of Psychiatry (2016)

Objective: The American Psychiatric Association (APA) identified Internet gaming disorder as a new potential psychiatric disorder and has recognized that little is known about the prevalence, validity, or cross-cultural robustness of proposed Internet gaming disorder criteria. In response to this gap in our understanding, the present study, a first for this research topic, estimated the period prevalence of this new potential psychiatric disorder using APA guidance, examined the validity of its proposed indicators, evaluated reliability cross-culturally and across genders, compared it to gold-standard research on gambling addiction and problem gaming, and estimated its impact on physical, social, and mental health. Method: Four survey studies (N=18,932) with large international cohorts employed an open-science methodology wherein the analysis plans for confirmatory hypotheses were registered prior to data collection. Results: Among those who played games, more than 2 out of 3 did not report any symptoms of Internet gaming disorder, and findings showed that a very small proportion of the general population (between 0.3% and 1.0%) might qualify for a potential acute diagnosis of Internet gaming disorder. Comparison to gambling disorder revealed that Internet-based games may be significantly less addictive than gambling and similarly dysregulating as electronic games more generally. Conclusions: The evidence linking Internet gaming disorder to game engagement was strong, but links to physical, social, and mental health outcomes were decidedly mixed.